Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Deferred Taxes (2024 - 2025)

Cytek Biosciences (CTKB) has disclosed Deferred Taxes for 2 consecutive years, with $38.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Deferred Taxes rose 1436.66% year-over-year to $38.6 million, compared with a TTM value of $33.6 million through Dec 2025, up 1262.75%, and an annual FY2025 reading of $33.6 million, up 1262.75% over the prior year.
  • Deferred Taxes was $38.6 million for Q4 2025 at Cytek Biosciences, up from -$2.6 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $38.6 million in Q4 2025 and bottomed at -$2.9 million in Q4 2024.